Skip to main content
Caplight Logo









rAAVen Therapeutics

rAAVen Therapeutics

Private
LundHealthcare & Life Scienceshttps://www.raaven.se/

Last Round

Accelerator

Oct 5, 2022

Momentum

Top 10%

of companies Caplight tracks

Company Overview

rAAVen Therapeutics is a biotechnology company that develops next-generation adeno-associated virus (AAV) vectors for precision gene therapy delivery.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

adeno-associated virusAAVviral vector engineeringcapsid engineeringgene therapyviral vector designtissue-specific deliverygene therapy platformviral vectorin vivo screeninggene deliveryvector discoverybiotech servicesrational peptide designDNA-barcoded libraries

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

rAAVen Therapeutics Comparables

Compare rAAVen Therapeutics with similar companies based on industry and business-model similarity.

rAAVen Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Capsigen
84%
Byongen Therapeutics
82%
Apertura Gene Therapy
81%

rAAVen Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
AcceleratorOct 5, 2022

Key People

Founding team and executive leadership

Magnus Henriks

CEO, Chief Business Officer

Executive Team

Marcus Davidsson

Chief Operating Officer

Executive Team

rAAVen Therapeutics Investors

Notable investors and investment history

rAAVen Therapeutics investors
InvestorRounds
SmiLe Venture HubAccelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors grew 110% MoM, reaching 1.1K.

  • Mar 2, 2026

    Monthly visitors increased 251% MoM.

rAAVen Therapeutics Filings

Explore SEC and related filing metadata, where available.

rAAVen Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about rAAVen Therapeutics's valuation, stock price, and market status.

Is rAAVen Therapeutics a public or private company?

rAAVen Therapeutics is a private company.

What is the current stock price of rAAVen Therapeutics?

rAAVen Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is rAAVen Therapeutics worth (valuation)?

Valuation information for rAAVen Therapeutics is not publicly available.

Can I buy rAAVen Therapeutics stock?

rAAVen Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was rAAVen Therapeutics's last funding round?

rAAVen Therapeutics's most recent funding round was Accelerator on October 5, 2022.

Who are the main investors in rAAVen Therapeutics?

Key investors in rAAVen Therapeutics include SmiLe Venture Hub.

Will rAAVen Therapeutics IPO soon?

No public IPO plans have been announced for rAAVen Therapeutics.

How can I track rAAVen Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor rAAVen Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersLund
Employee Range6
Year Founded2022
Last FundingOct 5, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?